ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
25
views
0
references
Top references
cited by
174
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,986
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
Author(s):
Takashi Seto
,
Katsuyuki Kiura
,
Makoto Nishio
,
Kazuhiko Nakagawa
,
Makoto Maemondo
,
Akira Inoue
,
Toyoaki Hida
,
Nobuyuki Yamamoto
,
Hiroshige Yoshioka
,
Masao Harada
,
Yuichiro Ohe
,
Naoyuki Nogami
,
Kengo Takeuchi
,
Tadashi Shimada
,
Tomohiro Tanaka
,
Tomohide Tamura
Publication date:
2013-06-01
Journal:
The Lancet Oncology
Publisher:
Elsevier BV
Read this article at
ScienceOpen
Publisher
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Nanopublications (single, attributable and machine-readable assertions in scientific literature)
Author and article information
Journal
DOI::
10.1016/S1470-2045(13)70142-6
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
1,986
A first-in-human phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLC
Authors:
K Kiura
,
T Seto
,
N Yamamoto
Selective ALK inhibitor alectinib (CH5424802/RO5424802) with potent antitumor activity in models of crizotinib resistance, including intracranial metastases
Authors:
T Kodama
,
T. Tsukaguchi
,
M. Hasegawa
…
A Phase I/II Study of Alk Inhibitor CH5424802 in Patients With Alk-Positive Nsclc; Safety and Efficacy Interim Results of the Phase II Portion
Authors:
M Nishio
,
K Kiura
,
K. Nakagawa
…
See all similar
Cited by
172
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Authors:
Toyoaki Hida
,
Hiroshi Nokihara
,
Masashi Kondo
…
Lorlatinib in ALK - or ROS1 -rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial
Authors:
Alice Shaw
,
Enriqueta Felip
,
Todd Bauer
…
Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer
Authors:
Alice Shaw
,
Leena Gandhi
,
Shirish Gadgeel
…
See all cited by
Version 1
Version 1
Version 1